Xiuning Le, MD, PhD, discusses the phase 3 trial, which follows the SOHO-01 trial of the oral TKI.
Expert Interviews
Watch video interviews with thoracic oncology experts to learn about the latest developments in lung cancer treatment and research.
Advertisement
Dr. Osarogiagbon shared insights on findings from the incidental lung nodule program and lung cancer screening program.
Jessica Bauman, MD, discusses a new analysis of the REACH PC study that she presented at ASCO 2025.
Jorge Nieva, MD, discusses a recent study that evaluated the impact of circadian rhythms on the efficacy of immunotherapy.
Stephen Liu, MD, shares his insights on the recent approval, the data behind it, and what the future may hold.
Jennifer Carlisle, MD, shares her institution’s experience with outpatient administration of the bispecific T-cell ...
Coral Olazagasti, MD, reflects on ASCO 2025 updates and the importance of bringing this news back to patients in the clinic.
Dr. Califano discusses what the study showed about baseline mechanisms of resistance to osimertinib and associated outcomes.
The study participants include those who have had at least one first-degree relative diagnosed with lung cancer.
Sophie Poznanski, PhD, shares insights from her ASCO 2025 presentation on the multifunctional antibody modality.
The study compared results from North America with global results by high-income and low- or middle-income countries.
Cheryl Czerlanis, MD, shares insights from the session on lung cancer screening that she chaired at ASCO 2025.
Palliative care researchers discuss differences in lung cancer treatment disparities across Hispanic patient subgroups.
Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025.
Jennifer Carlisle, MD, discusses amivantamab, and the multidimensional impact of toxicity management at ASCO 2025.
Coral Olazagasti, MD, shares why the ASCO Annual Meeting is a critical time to bring the field together.
Dr. Sanjay Juneja and Dr. Eric Singhi join a special episode of DDx for a candid conversation on a real patient case.
Dr. Singhi unpacks the thoracic oncology data and highlights coming up at this year's ASCO Annual Meeting.
Stephen V. Liu, MD, shares what he sees as the key upcoming highlights in thoracic oncology at the ASCO Annual Meeting.
Eric Singhi, MD, discusses the recent FDA approval and explains the associated new biomarker testing considerations.
Mara Antonoff, MD, explains the nuances of determining if a patient with oligometastatic disease is a candidate for surgery.
Ravi Rajaram, MD, MSc, discusses Medicaid expansion, timely access to care, regionalization effects, and remaining questions.
Michael R. Gieske, MD, discusses why Lung Cancer Action Week is a key time to promote screening and shares recent milestones.
Dr. Liu discusses his experience as co-chair of the Texas Lung Cancer Conference and shares key highlights.
Dr. Spira shares key data from cohort C of CHRYSALIS-2 that was presented at the European Lung Cancer Congress 2025.
Mara Antonoff, MD, discusses key advances and addresses common misconceptions about operating in oligometastatic disease.
Dr. Weiss noted the results in both feasibility and safety, particularly via injection, which had limited complications.
Dr. Mara Antonoff discusses why it's critical to offer information and updates on surgery for oligometastatic lung cancer.
Dr. Liu discusses key data and updates in EGFR-positive NSCLC from the European Lung Cancer Congress.
Nicolas Girard, MD, PhD, discusses data on subcutaneous amivantamab in patients with advanced NSCLC.
The session covered everything from new actionable immune checkpoints to vaccines, cellular therapies, and bispecifics.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.